Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

Core Insights - Eli Lilly and Company (LLY) has a market capitalization of $980.5 billion and is recognized for its diverse product lineup, particularly in the pharmaceutical sector [1] Stock Performance - LLY shares have increased by 28.7% over the past 52 weeks but have seen a decline of 2.8% year-to-date in 2026, underperforming compared to the S&P 500 Index, which returned 15.5% over the past year and increased by 1.9% in 2026 [2] - Compared to the Healthcare Select Sector SPDR ETF (XLV), which rose by 6% over the past year, LLY has outperformed but has lagged in 2026 [3] Growth Drivers - LLY became the first healthcare company to reach a $1 trillion market cap on November 21, primarily driven by its success in the weight-loss drug market, competing with Novo Nordisk [5] - The popularity of LLY's drugs, Zepbound and Mounjaro, along with promising results from a new oral weight-loss medication, have contributed to its growth [5] Earnings Expectations - For the fiscal year ending December 2025, analysts project an 82.8% year-over-year increase in adjusted EPS to $23.74, although LLY has a mixed earnings surprise history, surpassing estimates in three of the last four quarters [6] Analyst Ratings - LLY holds a consensus "Strong Buy" rating, with 22 out of 28 analysts recommending "Strong Buy," two "Moderate Buy," and four "Holds," indicating a positive shift in Wall Street's sentiment towards the stock [7] - Guggenheim analyst Seamus Fernandez maintained a "Buy" rating while slightly reducing the price target from $1163 to $1161, with a mean price target suggesting an 11.5% premium and a Street-high target indicating a 43.7% upside potential [8]